From Founding to Exit: A Life Science Business Founder's Perspective
Here's a glimpse of what to expect in this white paper:
WHITEPAPER
contributors:

Caroline Hoedemaker, MBA PE, Founder and Investor
tTAp a Life Science Accelerator; VALUEDsolutions (Moderator)

Wendy Perrow, MBA, Chief Executive Officer
AsclepiX Therapeutics (Panelist)

Robert Alonso, Founder & CEO
Mitochon (Panelist)

Richard Hughen, Chief Executive Officer
Cellth Systems (Panelist)
Richard Hughen’s thirty years of professional experience in the life science industry span three start-ups, a mid-cap and three Fortune 500 companies. He is currently CEO of Cellth Systems, a start-up based upon proprietary Circulating Tumor Cell (CTC) analysis technology. He is founder of Life Science Planning, a strategic consultancy for life science companies with focus on fast paced start-up, early stage and emerging growth companies. Ric was a member of the executive team that led start-up CSA Medical from a technology license (Navy), through product development, clinical trials, five FDA clearances, CE mark, four rounds of funding ($50M) and into a profitable commercial business. Before CSA Medical, he directed the marketing efforts for the $210 M molecular diagnostics business of Becton, Dickinson (BD). Learn More
Sponsored by:

